2YADEN Y, SLIWKOWSKI M X. Untangling the ErbB signaling network[J]. Nat Rev Mol Cell Biol, 2001, 2(2) : 127 -137.
3RSYMOND E, FAIVRE S, ARMAND J P, et al. Epidermal growth factor receptor tyrasine kinase as a target for anticancer therapy[J]. Drugs, 2001,20(11): 1 388.
4FORTUNATO C, GIAMPALOL T. A novel approach in the treatment of cancer:targeting the epidermal growth factor receptor[ J ]. Clin Cancer Res, 2001, 7(10) : 2 958 -2 970.
5HUNCHAREK M, KUPELNICK B. Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a metaanalysis [ J ]. Oncol Res, 2000, 12 (2): 107-102.
6WANG X J, LIAO H J, CHATTOPADHYAY A, et al. EGF -dependent translocation of green fluorescent protein - tagged PLC - gammal to the plasma membrane and endosomes [ J ]. Exp Cell Res, 2001,267(1): 28-36.
7MENDELSOHN J, BASELGA J. The EGF receptor family as targets for cancer therapy[ J]. Oneogene, 2000, 19 ( 56 ) : 6 550 - 6 565.
8TEBAR F, LLADO A. Role of calmodulin in the modulation of MAPKsignaling pathway and the transactivation of epidermal growth factor receptor mediated by PKC [ J ]. FEBSLett, 2002, 517(1/3) : 206 -210.
9SIROTNAK F M. Studies with ZD1839 in preclinical models[J]. Semin Oncol, 2003, 30(1 Suppl 1) : 12 -20.
10ONO M, KUWANO M. Molecular mechanisms of epidermal growth factor receptor(EGFR) activation and response to gefitinib and other EGFR targeting drugs[ J ]. Clin Cancer Res, 2006, 12 (24): 7 242 -7 251.
二级参考文献60
1[1]Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy[ J]. Oncogene, 2000,19(56) :6550 - 6565.
3[3]Normanno N, Maiello MR, de Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) :simple drugs with a complex mechanism of action? [J]. J Cell Physiol, 2003, 194( 1 ):13 - 19.
4[4]Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression[J]. Exp Cell Res ,2003,284(1) :99 - 110.
5[5]Graus Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimerization partner of all erbB receptors, is a mediator of lateral signaling[J]. EMBO J, 1997,16(7): 1647 - 1655.
6[6]Zvibel J, Brill S, Halpern Z, et al. Soluble and matrix-associated heparan sulfate proteoglycans increase expression of ErbB-2 and ErbB-3 in colon cancer cell lines[J]. Int J Cancer, 2001,91 (3) :316 -321.
7[7]Crovello CS,Lai C, Cantley LC, et al. Differential signaling by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2 [ J ]. J Biol Chem, 1998,273 (41 ): 26954 - 26961.
8[8]Gamett DC, Pearson G, Cerione RA, et al. Secondary dimerization between members of the epidermal growth factor receptor family[J]. J Biol Chem, 1997,272(18): 12052 - 12056.
9[9]Zhang P, Wang YZ, Kagan E, et al. Peroxynitrite targets the epidermal growth factor receptor, Raf-1, and MEK independently to activate M APK[ J]. J Biol Chem, 2000,275 (29) :22479 - 22486.
10[10]Datta SR,Brunet A,Greenberg ME. Cellular survival:a play in three Akts[ J]. Genes Dev, 1999,13(22) :2905 - 2927.
2TSAI C, CHANG K, PERNG R, et al. Correlation of intrinsic chemoresisitance of non-small cell lung cancer celI lines with HER-2 /neu gene expression but not with ras gene mutation[J]. J Natl cancer Inst, 1993, 85 : 897- 901.
